Evidence-Based Treatment for HIV-Associated Dementia and Cognitive Impairment
Author Information
Author(s): Ronald J. Ellis
Primary Institution: University of San Diego, California, USA
Hypothesis
Does adding abacavir to an existing antiretroviral regimen improve brain function in patients with HIV-associated dementia?
Conclusion
The addition of abacavir did not show a statistically significant improvement in brain function compared to placebo.
Supporting Evidence
- Patients in both treatment arms improved substantially.
- The median change in neuropsychological performance index exceeded half a standard deviation.
- Virologic suppression improved more in the abacavir group than in the placebo group.
Takeaway
The study tested if a new medicine could help people with brain problems from HIV, but it didn't work better than a sugar pill.
Methodology
Randomized, double-blind, placebo-controlled trial over 12 weeks.
Potential Biases
Participants' regimens were mostly failing, which may have biased results.
Limitations
The study's goals were limited by rapid developments in HIV treatment and the ineffectiveness of single-agent therapy.
Participant Demographics
HIV-positive patients with HIV-associated dementia who were on stable background therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website